Recombinant Anti-EGFR × Anti-HER3 Bispecific Antibody (CrossMab) has been generated by applying the Crossmab format to generate an IgG shaped entity that binds each ligand with one arm. This BsAb is capable of blocking two HER family members, EGFR and HER3. BsAb-mediated simultaneous interference with two (or more) RTK signaling pathways, by inactivating either the RTKs or their ligand, can reduce the possibility of such escape mechanisms and, hence, improve therapeutic efficacy. It was designed for the treatment of breast, colon, lung, or pancreatic cancers.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
TAND-L032 | Recombinant Anti-EGFR × Anti-HER3 Bispecific Antibody (Tandem Diabody) | FuncS, Promising therapeutic agent | Tandem Diabody |
There are currently no Customer reviews or questions for CROSS-L013. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.